Join us for a comprehensive webinar featuring experts in epigenetics and assay development, focusing on the scientific foundations and applications of Nucleosome Quantification (Nu.Q®) Technology in the realms of drug development and disease monitoring.
Eric A. Ariazi, PhD and Terry Kelly, PhD discuss how nucleosome-based markers are poised to accelerate oncology clinical trials, offering broader applications for monitoring both toxicity and efficacy.
This session explores the critical contributions of Nu.Q® Technology to clinical epigenetics research, emphasizing its role in the identification and validation of biomarkers for epigenetic drug discovery. The technology’s capability in monitoring treatment responses and its utility in elucidating the underlying mechanisms of disease processes are discussed.
Key Topics Include:
- Next-Generation Epigenetic Immunoassay for Quantitative Assessment of Circulating Nucleosomes
- Nu.Q Technology for determining levels of circulating nucleosomes
- Pre-clinical through Clinical Development of Circulating Nucleosomes as Pharmacodynamic Biomarkers in Oncology Trials
- Histone PTMs at biomarkers for therapeutics targeting chromatin regulators
- Liquid biopsy to monitor target engagement of inhibitors of PRC2 subunits including histone methyl transferase EZH2 and its allosteric regulator EED
- Precision oncology strategy for selecting patients with H3K27me3 accumulation
- PD-1/PD-L1 checkpoint inhibitor combination with EZH2i/EEDi
- Expanding Utility of Circulating Nucleosomes to Monitor/Predict Adverse Reactions to CAR-T cell therapy
- Neutrophil release of inflammatory mediators and decondensed DNA (NETosis) before and during the onset of cytokine release syndrome (CRS)
- Monitoring NETosis with Nu.Q
By the end of this discussion, attendees will:
- Gain a nuanced understanding of the emerging opportunities in biomarker-driven, epigenetic therapeutic development.
- Acquire insights into the future potential of nucleosome markers as versatile tools for cancer response and toxicity monitoring.
Presenters
Consultant
Volition
Eric A. Ariazi, PhD, is a distinguished Translational Medicine Scientist with 25+ years of experience spanning academia and industry.
Chief Innovation Officer/Chief Scientific Officer
VolitionRx/Volition America
Dr. Terry Kelly is the Chief Innovation Officer for VolitionRx and Chief Scientific Officer for Volition America.
Production Partner
Volition
Volition is a leading epigenetics biomarker company, renowned for its proprietary liquid biopsy immunoassay approach to profiling nucleosomes.
Additional Content From Scientist.com
How to Avoid Expensive Redesign Cycles in Antibody Discovery
Learn how integrated antibody discovery and engineering strategies can accelerate the path from hit to optimized lead in less than 12 months while minimizing costly redesign cycles.
Beyond Exposure: Integrating PK/PD for Translational Predictive Power
Learn to integrate PK/PD modeling and strategic biomarkers to bridge the translational gap. Improve clinical predictability for NCEs, ADCs, and large molecules in this technical webinar.
Advancing the Manufacture of Mesenchymal Stromal Cells and Derived Extracellular Vesicles in Stirred-Tank Bioreactors Through Enhanced Bioprocess Control
Learn how to scale the production of MSCs and extracellular vesicles using bioreactor control and real-time monitoring for more consistent therapies.